Recruiting studies: Progressive Astrocytoma Idh Mutant Grade 4

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT07468136 Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progress
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT06815029 GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma an
Phase 2 · 1 location(s) · Mayo Clinic · NCT07301268 Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurre
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT07544992 A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma
Phase 1/Phase 2 · 16 location(s) · Debiopharm International SA · NCT05765812

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.